Case ReportsSomatostatin analogs in pregnant patients with neuroendocrine tumorMeoni, Giuliaa; Giommoni, Elisaa; Petreni, Paolob; Pillozzi, Serenaa; Mazzoni, Francescaa; Pellegrini, Elisaa; Brugia, Marcoa; Lunghi, Alicec; Muto, Andread; Antonuzzo, LorenzoaAuthor Information aMedical Oncology Unit, Careggi University Hospital, Firenze bMedical Oncology Unit, Alta Val d’Elsa Hospital, Poggibonsi cMedical Oncology Unit, Division of Medical Oncology, San Luca Hospital, Lucca dMedical Oncology Unit, Azienda Ospedaliero di Rilevo Nazionale San Giuseppe Moscati, Avellino, Italy Received 20 April 2020 Revised form accepted 1 June 2020 Correspondence to Lorenzo Antonuzzo, MD, PhD, Medical Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Largogo Brambilla, 3, 50134 Florence, Italy, Tel: +39 055 7949648; fax: +39 055 7948394; e-mail: [email protected], [email protected] Anti-Cancer Drugs: November 2020 - Volume 31 - Issue 10 - p 1096-1098 doi: 10.1097/CAD.0000000000000967 Buy Metrics Abstract Somatostatine analogs (SSAs) are currently indicated in the treatment of acromegaly and neuroendocrine tumors (NETs). Actually, pregnancy in patients with acromegaly and NETs does not represent an exceptional event because reproductive behavior has changed in the last decades and patients with NETs show more frequently long-term survival. The safety profile of SSAs during pregnancy is still controversial. Concerning acromegaly, based on case reports and series, SSAs administration during pregnancy seems to be relatively well tolerated. Concerning patients with NETs, up to date only one patient with NET receiving SSA during pregnancy has been reported in literature. We report two cases of gastroenteropancreatic-NET patients receiving SSA lanreotide for the entire course of their pregnancy, with favorable outcomes for both mothers and babies. Our experience supports the possibility to continue safely SSA lanreotide during pregnancy in patients with NET. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.